


We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target

> Göran Forsberg, CEO March 2021

Safe Harbour Statement




Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forwardlooking statements will prove to be correct. Prospective investors should not place undue reliance on forwardlooking statements. They speak only as at the date of this Investor Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company undertakes no obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of the Investor Presentation.





I. INTRODUCTION

Cantargia – Opportunity to save lives and create value





Cantargia highlights



UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT

- Positive interim data set response rates higher than historical control
- First in class antibody with broader MOA than competitors



VISION OF BECOMING AN IMPORTANT PART IN FUTURE CANCER TREATMENTS

• Combination strategy based on synergies with established therapies



PLATFORM WITH MANY POTENTIAL THERAPEUTIC AREAS

- Target IL1RAP found on most solid tumor forms and leukemia
- IL1RAP signalling (IL-1, IL-33 and IL-36) in large number of diseases



HIGHLY RELEVANT RESEARCH WITHIN CLINICALLY VALIDATED MECHANISMS

• Focus on opportunities with major unmet medical need



ROBUST PATENT PORTFOLIO

 Global patent families on IL1RAP as antibody target in oncology until 2032 and CAN04 until 2035



NASDAQ STOCKHOLM MAIN LIST ~10,000 SHAREHOLDERS AND LONG TERM INVESTORS

- Market cap: SEK 3.0bn (USD ~360m) (29 Mar-21)
- Cash: SEK 903m (USD 108m) (31 Dec-20)

Current owners (30 Dec 2020)


Swedbank Robur Funds	9.7%
4th AP fund	7.7%
Alecta	6.6%
1st AP fund	6.3%
Öhman Bank S.A.	5.3%
Handelsbanken fonder	3.8%
Avanza Pension	3.8%
Sunstone LSV	3.5%
Morgan Stanley	2.0%
JP Morgan	1.8%
Others	49.5%





II. LEAD ANTIBODY CAN04

Cantargia addresses NSCLC & PDAC




SIGNIFICANT UNMET NEEDS IN LUNG AND PANCREATIC CANCER




Inflammatory IL-1 pathway validated as target

Cantos trial (n=10,061)

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67% and death by 77%
- Reduced non-lung cancer death by 37%




Canakinumab phase III trials



Oligination (Construction)


ROLE OF IL-1B IN EARLY STAGE CANCER TWO PHASE III TRIALS AS WELL AS PHASE I-II TRIALS ONGOING CAN04 PROVIDE MORE POTENT BLOCKADE OF PATHWAY

CAN04 – Dual anticancer mechanism



Inhibition of IL-1 signaling


NSCLC



CAN04 BLOCKS BOTH FORMS OF IL-1 AND STIMULATES DIRECT KILLING OF CANCER CELLS




CAN04 – Differentiated and superior MOA



Cancer conte	ext	IL-1α			IL-1β		comment	
Localization		Cellbound and solubleCancer cells and stroma		• Sc	• Soluble		 IL-1α trigger and IL-1β enhance inflammation Often work in pair 	
Function	• IL-1,				 No known difference in signal induced by the 2 forms 			
 Clinical data from blockade 	m • Signa NSCL	ll of benefit ir C	n CRC and		ANTOS: reduce lung cancer cidence and death			
Company	Compound	IL-1α	IL-1β	ADCC	Indication/dev phase			
Cantargia (CAN04	++	++	++	Pancreatic cancer, NSCLC p	hase lla		
Xbiotech/ S Janssen	Xilonix	++	-	+	 Autoimmunity, dermatolog Pancreatic cancer, phase I 	у		
	Canakinumab Gevokizumab	-	++	-	 Autoimmunity, registered NSCLC, phase III Cancer comb, phase II 			
Flame Biosci.	FL-101	-	++	-	NSCLC			
Buzzard	Isunakinra	++	++	-	Cancer phase I			
SOBI	Kineret	++	++	-	• Autoimmunity, reg			
Regeneron/ Kiniksa	Rilonacept	++	++	-	 Autoimmunity, reg Pericarditis			
R-Pharm	RPH-104	+	++	-	Pericarditis, inflammatory c	lisease	eantargi	

CAN04 – Mechanism of action




CAN04 BLOCKS BOTH FORMS OF IL-1 AND CAN ERADICATE CELLS MEDIATING THE EFFECTS OF IL-1

Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated Fibroblast. NK = Natural Killer. MCP = Monocyte Chemoattractant Protein. MMP = Matrix Metallopeptidase. IL = Interleukin. VEGF = Vascular Endothelial Growth Factor




Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)



SYNERGY WITH CHEMOTHERAPY IN LINE WITH CURRENT DEVELOPMENT STRATEGY



Tumor shrinkage – NSCLC combination




- \rightarrow CAN04 in combination with gem/cis in 1st line chemotherapy
- 6 of 9 evaluable patients with metastatic non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (67% vs historical control data 22–28%)
- \rightarrow The complete response has lasted more than 1 year
- 5 patients were second line to pembrolizumab monotherapy,
 4 patients first line
- No major side effects observed except those from chemotherapy or CAN04 alone. Neutropenia frequency higher than expected from chemo (treated with dose reductions/GCSF)



POSITIVE INTERIM DATA, RECRUITMENT CONTINUE FOR PRIMARY ANALYSIS BROADENING OF NSCLC DEVELOPMENT INTO ADDITIONAL MARKET SEGMENTS




Positive interim data-pancreatic cancer



- \rightarrow CAN04 combination with gemcitabine/abraxane in 1st line PDAC
- → 8 out of 20 evaluable patients with metastatic PDAC showed response (40% vs historical control data 23%). Two responses durable for 12 months
- No major side effects were observed apart from those expected with chemotherapy or CAN04 alone. Neutropenia frequency higher than expected from chemo (treated with dose reductions/GCSF), fatigue and neuropathy lower than expected

FULLY RECRUITED -31 PATIENTS FOR PRIMARY ANALYSIS ONGOING EXTENSION PHASE 20–40 PATIENTS TO STUDY DOSE/RESPONSE PREPARATIONS FOR LATE STAGE DEVELOPMENT INITIATED




- Two patients had tumor shrinkage of 39% and 24% after initial PD.
 Both recorded as SD
- → CA19-9 decreased by 92% and 71%. CA19-9 is a biomarker for tumor burden

NOTABLE RESPONSE PROFILE DEVIATING FROM CHEMO ALONE SUGGEST ADDITIONAL EFFECT FROM CAN04



IL1RAP in several cancer with high medical need

IL1RAP





- → Biomarker studies ongoing, identify patients most likely to respond
- → Opportunity to expand development in additional cancer forms with high unmet medical need

CAN04 DEVELOPMENT CAN BE EXPANDED TO ADDITIONAL INDICATIONS ONWARDS



US Phase I clinical trial

 \rightarrow First patient started 2020


- → Combination with checkpoint inhibitor in patients no longer responding to PD1/PDL-1 therapy
- \rightarrow Primary endpoint safety, secondary endpoints include biomarkers and efficacy
- → Indications include NSCLC, HNSCC, malignant melanoma and bladder cancer (18 patients)
- \rightarrow Strong US centers, Coord investigator Prof Roger Cohen, UPenn
- → https://clinicaltrials.gov/ct2/show/NCT04452214



TRIAL DESIGNED TO ADVANCE CAN04 OUTSIDE CHEMOTHERAPY COMBINATIONS IMPORTANT STEP FOR COMBINING CAN04 WITH IO AND CHEMOTHERAPY



CAN04–Broadening development








III. UNTAPPED POSSIBILITIES IN AUTOIMMUNE DISEASES

CAN10 – New development project

- \rightarrow IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36
- Unique anti-inflammatory activity observed in different mouse models (myocarditis, psoriasis, inflammation)
- → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on scientific rational, medical need, development opportunity and competition
- ightarrow Clinical trials start early 2022




UNIQUE OPPORTUNITY FOR CAN10 IDENTIFIED IN LIFE-THREATENING DISEASES



CAN10 counteract inflammation in disease model

Total back score



- → Mechanistic proof of concept for IL1RAP blockade in inflammatory driven psoriasis model
- ightarrow Effect not dependent on IL-1 β blockade
- → Effects in myocarditis model to be presented at conference during Q2 2021 – CAN10 superior to IL-1 blockade.
- \rightarrow Well tolerated as single dose up to 50 mg/kg (tox model)

CAN10 HAS UNIQUE ANTI-INFLAMMATORY PROPERTIES





IV. MILESTONES AND SUMMARY

Cantargia has several near-term value inflection points

Newsflow over next 6–9 months

CAN04

- \rightarrow New results PDAC, NSCLC and Keytruda combination
- \rightarrow Next steps combination therapy PDAC and NSCLC
- \rightarrow Phase IIa biomarker/biopsy results
- \rightarrow Start new clinical trials
 - FOLFIRINOX combination PDAC
 - Basket trial NSCLC and new indications like TNBC

CAN10

- \rightarrow Preclinical progress
- → Development milestones



SIGNIFICANT DATA TO SECURE NEWSFLOW



Cantargia highlights

UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT

- First in class antibody with broader MOA than competitors
- Positive interim data set and further clinical milestones during 2021



VISION OF BECOMING AN IMPORTANT PART IN FUTURE CANCER TREATMENTS

• Combination therapy strategy based on synergies with established therapies



PLATFORM WITH MANY POTENTIAL THERAPEUTIC AREAS

Cancer and large number of autoimmune/inflammatory diseases



HIGHLY RELEVANT RESEARCH WITHIN CLINICALLY VALIDATED MECHANISMS

• Focus on opportunities with major unmet medical need



ROBUST PATENT PORTFOLIO – GRANTED IP FOR THERAPEUTIC TARGET IL1RAP AND CAN04

Global patent families – antibody target in oncology (2032) and CAN04 (2035)



NASDAQ STOCKHOLM'S MAIN LIST ~10,000 SHAREHOLDERS AND LONG-TERM INVESTORS

- Market cap: SEK 3.0bn (USD ~360m) (29 Mar-21)
- Cash: SEK 903m (USD 108m) (31 Dec-20)



